ArticlePharmaceutics2022

Combined Transcriptomic and Proteomic Profiling to Unravel Osimertinib, CARP-1 Functional Mimetic (CFM 4.17) Formulation and Telmisartan Combo Treatment in NSCLC Tumor Xenografts.

Ramesh Nimma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.